← All Intra-cellular Therapies, INC filings

Intra-cellular Therapies, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

ITCI
Intra-cellular Therapies, INC
10-Q: Intra-Cellular Therapies Reports Strong Q3 Revenue Growth Driven by CAPLYTA Sales
Intra-Cellular Therapies reports a 39% increase in product sales for the third quarter of 2024, driven by continued growth in CAPLYTA prescriptions.
ITCI
Intra-cellular Therapies, INC
10-Q: Intra-Cellular Therapies Reports Strong Q2 Revenue Growth and Positive Clinical Trial Results
Intra-Cellular Therapies reports a 46% increase in product sales for the second quarter of 2024 and positive results from Phase 3 trials for lumateperone in major depressive disorder.
ITCI
Intra-cellular Therapies, INC
10-Q: Intra-Cellular Therapies Reports Strong Q1 Revenue Growth, Advances Clinical Programs
Intra-Cellular Therapies saw a 53% increase in product sales in the first quarter of 2024, while also progressing its clinical trials for various neurological and psychiatric disorders.